earnings
confidence high
sentiment neutral
materiality 0.55
Acurx Pharma Q1 net loss $2.7M ($0.26/shr); Phase 2b CDI trial progressing
Acurx Pharmaceuticals, Inc.
2022-Q1 EPS reported
-$0.26
- Cash $11.1M at March 31, 2022, down from $13.0M at Dec 31, 2021.
- Net loss $2.7M vs $1.5M YoY; R&D costs rose to $0.8M from $0.1M on Phase 2b trial costs.
- Phase 2b CDI trial enrollment ongoing; completion expected late H2 2022.
- Protocol amended to add exploratory Extended Clinical Cure endpoint at day 56 and day 84.
- Shares outstanding 10,263,202 as of March 31, 2022.